Trial Profile
Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation; Diabetic macular oedema; Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms COVERT
- 27 Apr 2021 Planned End Date changed from 28 Feb 2020 to 28 Feb 2024.
- 27 Apr 2021 Planned primary completion date changed from 28 Feb 2020 to 28 Feb 2024.
- 17 Sep 2019 Status changed from not yet recruiting to recruiting.